Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVS
stocks logo

NVS

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
13.94B
+11.38%
2.342
+18.89%
13.40B
+4.52%
2.166
+5.12%
13.68B
+4.04%
1.961
-0.95%
Estimates Revision
The market is revising Upward the revenue expectations for Novartis AG (NVS) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by 9.53%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.57%
In Past 3 Month
Stock Price
Go Up
up Image
+9.53%
In Past 3 Month
5 Analyst Rating
down Image0
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 107.00 USD with a low forecast of 88.00 USD and a high forecast of 116.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
1 Sell
Hold
down Image0
Current: 119.450
sliders
Low
88.00
Averages
107.00
High
116.00
down Image0
Current: 119.450
sliders
Low
88.00
Averages
107.00
High
116.00
UBS
Matthew Weston
Strong Buy
to
Hold
Downgrades
n/a
2025-02-13
Reason
UBS
Matthew Weston
Price Target
n/a
2025-02-13
Downgrades
Strong Buy
to
Hold
Reason
UBS analyst Matthew Weston downgraded Novartis to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company's key growth drivers are already reflected in consensus expectations.
Erste Group
Hans Engel
Strong Buy
to
Hold
Downgrades
n/a
2024-11-19
Reason
Erste Group
Hans Engel
Price Target
n/a
2024-11-19
Downgrades
Strong Buy
to
Hold
Reason
Erste Group downgraded Novartis to Hold from Buy.
BMO Capital
Etzer Darout
Hold
Maintains
$118 → $120
2024-10-30
Reason
BMO Capital
Etzer Darout
Price Target
$118 → $120
2024-10-30
Maintains
Hold
Reason
B of A Securities
Graham Perry
Strong Buy
to
Hold
Downgrades
$135 → $130
2024-09-11
Reason
B of A Securities
Graham Perry
Price Target
$135 → $130
2024-09-11
Downgrades
Strong Buy
to
Hold
Reason
Goldman Sachs
James Quigley
Strong Buy
to
Hold
Downgrades
$119 → $121
2024-09-05
Reason
Goldman Sachs
James Quigley
Price Target
$119 → $121
2024-09-05
Downgrades
Strong Buy
to
Hold
Reason
Jefferies
Peter Welford
Strong Buy
to
Hold
Downgrades
n/a
2024-09-03
Reason
Jefferies
Peter Welford
Price Target
n/a
2024-09-03
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novartis AG (NVS.N) is 0.00, compared to its 5-year average forward P/E of 13.64. For a more detailed relative valuation and DCF analysis to assess Novartis AG 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
13.64
Current PE
0.00
Overvalued PE
15.47
Undervalued PE
11.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
11.68
Current EV/EBITDA
11.38
Overvalued EV/EBITDA
12.56
Undervalued EV/EBITDA
10.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
3.95
Current PS
4.34
Overvalued PS
4.29
Undervalued PS
3.61

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NVS News & Events

Events Timeline

(ET)
2025-06-12
12:40:51
Senators to propose ban on drug ads to consumers, WSJ reports
select
link
2025-06-12
06:13:43
Novartis announces results from APPULSE-PNH study of Fabhalta
select
2025-06-12
06:00:36
RFK Jr. names eight members to vaccine panel, WSJ reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-13Benzinga
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

  • Novo Nordisk's Development Plans: Novo Nordisk A/S is advancing its amycretin drug into phase 3 development for weight management, based on regulatory feedback, with plans to initiate the program in early 2026.

  • Market Performance and Challenges: Despite becoming the largest European company by market capitalization, Novo Nordisk has faced setbacks including disappointing trial results and a decline in stock value, leading to a CEO replacement search.

Preview
9.0
06-13Benzinga
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

  • Study Results: Novartis AG announced positive results from the Phase 3B APPULSE-PNH study, showing that their oral monotherapy Fabhalta (iptacopan) significantly improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) after switching from anti-C5 therapies, with 92.7% achieving Hb ≥12g/dL and no transfusions required during the study.

  • Clinical Significance: The study demonstrated that Fabhalta not only improved hemoglobin levels but also led to meaningful reductions in fatigue and maintained control over hemolysis, highlighting its potential as a more convenient treatment option compared to traditional intravenous anti-C5 therapies.

Preview
3.0
06-13NASDAQ.COM
Guru Fundamental Report for NVS

  • Investment Rating: Novartis AG (ADR) (NVS) has received a 75% rating from Validea's Multi-Factor Investor model, indicating strong interest based on its fundamentals and valuation within the Biotechnology & Drugs industry.

  • Pim van Vliet's Strategy: The model, developed by Pim van Vliet, focuses on low volatility stocks with high momentum and net payout yields, highlighting that low volatility stocks can outperform higher volatility ones with less risk.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novartis AG (NVS) stock price today?

The current price of NVS is 119.45 USD — it has decreased -1.09 % in the last trading day.

arrow icon

What is Novartis AG (NVS)'s business?

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

arrow icon

What is the price predicton of NVS Stock?

Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 107.00 USD with a low forecast of 88.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novartis AG (NVS)'s revenue for the last quarter?

Novartis AG revenue for the last quarter amounts to 13.59B USD, increased 12.09 % YoY.

arrow icon

What is Novartis AG (NVS)'s earnings per share (EPS) for the last quarter?

Novartis AG. EPS for the last quarter amounts to 1.82 USD, increased 38.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novartis AG (NVS)'s fundamentals?

The market is revising Upward the revenue expectations for Novartis AG (NVS) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by 9.53%.
arrow icon

How many employees does Novartis AG (NVS). have?

Novartis AG (NVS) has 76057 emplpoyees as of June 14 2025.

arrow icon

What is Novartis AG (NVS) market cap?

Today NVS has the market capitalization of 234.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free